U.S. markets closed

Inspire Medical Systems, Inc. (INSP)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
221.22+3.68 (+1.69%)
At close: 4:00PM EDT

221.22 -0.02 (-0.01%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Hanging Man

Hanging Man

Previous Close217.54
Open218.88
Bid215.01 x 800
Ask231.09 x 800
Day's Range215.00 - 222.63
52 Week Range64.16 - 252.25
Volume116,604
Avg. Volume237,740
Market Cap6.174B
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateMay 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est253.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    Investing in Sleep Apnea Companies

    In this episode of Industry Focus: Wildcard, join Motley Fool contributor Brian Feroldi and host Emily Flippen as they talk about three companies trying to treat sleep apnea: ResMed (NYSE: RMD), Inspire Medical (NYSE: INSP), and Vivos Therapeutics (NASDAQ: VVOS). To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Today is Wednesday, March 24th, and I am your host, Emily Flippen.

  • Inspire Medical Systems, Inc. to Report First Quarter 2021 Financial Results on May 4, 2021
    GlobeNewswire

    Inspire Medical Systems, Inc. to Report First Quarter 2021 Financial Results on May 4, 2021

    MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2021 after the close of trading on Tuesday, May 4. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. Tuesday, May 4th @ 5:00 p.m. Eastern Time:Domestic: 877-407-0792International: 201-689-8263Conference ID: 13717525Webcast: http://public.viavid.com/index.php?id=143909 About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact:Bob YedidLifeSci Advisorsinspire@lifesciadvisors.com646-597-6989

  • FDA Approves Inspire Medical’s Physician Programmer Platform; Street Says Buy
    SmarterAnalyst

    FDA Approves Inspire Medical’s Physician Programmer Platform; Street Says Buy

    Medical technology company Inspire Medical Systems received approval from the U.S. Food and Drug Administration (FDA) for the Inspire physician programmer platform. Inspire Medical Systems (INSP) is focused on minimally invasive solutions for treating patients with obstructive sleep apnea. The approved platform provides four major enhancements to the company’s existing product. These enhancements include guided workflows, a new programmer cable that allows for ease of use, and improved telemetry range. The platform enables interface with Inspire cloud and uploading patient reports. It also supports the further integration of Inspire cloud, which can potentially provide remote programming, a feature that is currently under development. Inspire Medical Systems’ President and Chief Executive Officer, Tim Herbert, said, “In addition to the recently announced approval for the Inspire two-cision procedure, the launch of our new physician programmer platform further demonstrates our long-term commitment to patients through Inspire’s continued investment in our innovative technologies.” Herbert added, “The new Inspire physician programmer platform provides multiple key benefits for physicians when managing their patients’ sleep apnea treatment with Inspire therapy.” (See Inspire Medical stock analysis on TipRanks) Last month, Oppenheimer analyst Suraj Kalia reiterated a Hold rating on the stock without assigning a price target. Kalia said, “Inspire is the first company to commercialize hypoglossal nerve stimulation (HGNS) to pull the tongue forward, therefore improving airway patency in obstructive sleep apnea (OSA) patients.” Turning to the rest of the Street, the stock has a Strong Buy consensus rating alongside an average analyst price target of $253.25 (22.3% upside potential), based on 6 Buys and 2 Holds. Shares have gained about 226.2% over the past year. Related News: TEGNA Bumps Up Quarterly Dividend By 36% Palomar To Buy Back $40M In Stock; Shares Gain After-Hours Globe Life Ramps Up Quarterly Dividend By 5.3% More recent articles from Smarter Analyst: Campbell Soup To Sell Plum Organics Brand KKR Snaps Up The Exchange In San Francisco For $1B Walgreens Rises After 2Q Profit Win, Lifts Guidance Dave & Buster’s Paces Past 2Q Estimates Despite COVID-19 Headwinds